The novel mechanism provided in this study is different from previous reports that PTGS2 might contribute to drug resistance through promotion of EMT in NSCLC or elevation of P-glycoprotein expression in other tumors (Hosomi et al., 2000; Arunasree et al., 2008; Gu and Chen, 2012). The gene discussed is PTGS2; the disease is non-small cell lung carcinoma.